Hypertension and Vascular Biology Fellowship

The Hypertension and Vascular Biology Research Team in front of the Steven Spielberg Building (L-R): Matthew Hakimi, MD, Mohamad Rashid, Katie Sy, Florian Rader, MD, Ronald Victor, MD, O’Neil Mason, MD, Prizzi Moy, Brent Hsu, Davontae Foxx-Drew, Kathleen Lynch and Mary Rezk-Hanna.

Program Overview

The objective of the Cedars-Sinai Research and Clinical Fellowship in Hypertension and Vascular Biology is to provide an experiential learning environment for obtaining research competency in translational research and clinical trials. The program is designed for a diverse group of physician-scientists who have completed their general medical training and are interested in pursuing one of the following medical subspecialties:

  • Cardiology
  • Nephrology
  • Endocrinology
  • General internal medicine

We believe that encouraging the fellow's potential to generate crucial medical evidence that supports practice decisions — rather than simply absorb the published evidence — is integral to optimizing treatment outcome and keeping pace with the increased prevalence of cardiovascular diseases.

The fellow is mentored in all aspects of a research project, including the following: critically appraising study designs, designing study protocols, implementing strategies for data collection and analysis and interpreting complex translational research data. The fellow is expected to build a high-quality research portfolio, including abstract presentations at national meetings, grant writing, and manuscript publications in peer-reviewed journals.

The fellow will be exposed to challenging cases of treatment-resistant primary hypertension and patients with secondary hypertension who are referred to our weekly Hypertension Clinic, staffed by faculty members of the Cedars-Sinai Hypertension Center.

This fellowship is for two years. At the end of the two-year program, the fellow gains sufficient clinical experience to sit in for the American Society of Hypertension qualifying examination in clinical hypertension. A third year is available for those who wish to devote an additional year to full-time research.